Aaron Crowley
Overview
Explore the profile of Aaron Crowley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masri A, Chen Y, Colavecchia A, Benjumea D, Crowley A, Jhingran P, et al.
J Am Heart Assoc
. 2025 Jan;
14(2):e033251.
PMID: 39817522
Background: The coexistence of transthyretin cardiac amyloidosis (ATTR-CA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. We aimed to characterize clinical outcomes in AS plus...
2.
Stone G, Valgimigli M, Erlinge D, Han Y, Steg P, Stables R, et al.
J Am Coll Cardiol
. 2024 Oct;
84(16):1512-1524.
PMID: 39384262
Background: In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI)...
3.
Hsu W, Crowley A, Parzynski C
BMC Med Res Methodol
. 2024 Sep;
24(1):203.
PMID: 39272007
Background: Evaluating outcome reliability is critical in real-world evidence studies. Overall survival is a common outcome in these studies; however, its capture in real-world data (RWD) sources is often incomplete...
4.
Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, et al.
Adv Ther
. 2024 Jul;
41(8):3299-3315.
PMID: 38958845
Introduction: For patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after osimertinib and platinum-based chemotherapy (PBC), no uniformly...
5.
Kato T, Ines M, Minamisawa M, Benjumea D, Keohane D, Alvir J, et al.
ESC Heart Fail
. 2024 May;
11(5):2881-2888.
PMID: 38783561
Aims: This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV)...
6.
Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg P, et al.
Circulation
. 2023 Sep;
148(16):1207-1219.
PMID: 37746717
Background: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers....
7.
Bhambri R, Colavecchia A, Bruno M, Chen Y, Alvir J, Roy A, et al.
Am J Cardiovasc Drugs
. 2023 Feb;
23(2):197-206.
PMID: 36780092
Background: Tafamidis was approved for the treatment of hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on findings from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)....
8.
Vincent F, Thourani V, Ternacle J, Redfors B, Cohen D, Hahn R, et al.
Circ Cardiovasc Qual Outcomes
. 2022 Jan;
15(1):e007948.
PMID: 35041482
Background: Circadian rhythms may influence myocardial tolerance to ischemia-reperfusion phenomena occurring during cardiac procedures. While conflicting results exist on the effect of time-of-day on surgical aortic valve replacement (SAVR), afternoon...
9.
Chau K, Chen S, Crowley A, Redfors B, Li D, Hahn R, et al.
EuroIntervention
. 2021 Sep;
17(13):1053-1060.
PMID: 34483095
Background: Moderate or worse paravalvular regurgitation (PVR) post transcatheter aortic valve replacement (TAVR) is associated with increased mortality. The mechanisms by which this occurs are not fully understood. Aims: The...
10.
Myat A, Hildick-Smith D, de Belder A, Trivedi U, Crowley A, Morice M, et al.
EuroIntervention
. 2021 Jul;
17(13):1081-1090.
PMID: 34212863
Background: The EXCEL trial reported similar five-year rates of the primary composite outcome of death, myocardial infarction (MI), or stroke after percutaneous coronary intervention (PCI) compared with coronary artery bypass...